Date: Jul 06, 2012 Source: Bloomberg (
click here to go to the source)
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co. Ltd. Announce
Worldwide Agreement to Develop Novel Digital Health Products
Business Wire
REDWOOD CITY, Calif. & TOKYO -- July 06, 2012
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd., announced
they have entered into an exclusive worldwide license and collaboration
agreement to develop and commercialize a new category of medicines. These new
medicines will be based on Otsuka's pharmaceutical products and Proteus's
digital health feedback system incorporating Proteus's novel sensor-based
technologies. Under the agreement, Proteus and Otsuka have entered an
exclusive collaboration to develop commercial products in two defined
therapeutic areas of high unmet medical need. Otsuka has also been granted a
non-exclusive license to utilize Proteus technology in its clinical research
and development activities.
Financial terms of the agreement were not disclosed.
The Proteus digital health feedback system combines wearable and ingestible
sensor technologies that together are designed to help improve patients'
health habits. Detailed information, including when a medication has been
taken as well as activity and rest patterns, is captured and delivered to a
secure database. The information, accessible from a variety of platforms such
as mobile phones with consent granted by the patient, is designed to help
patients and their caregivers better manage their conditions and to help
clinicians provide more effective care.
About Proteus Digital Health, Inc.
Proteus Digital Health, formally known as Proteus Biomedical, Inc., believes
in better health, powered by you. Proteus's wearable and ingestible sensor
technology is used to deliver digital medications and other health and
wellness products. Headquartered in Redwood City, CA, Proteus partners with
and licenses to leading companies to commercialize digital health products,
including Otsuka, Novartis, Avery Dennison, Medtronic, ON Semiconductor,
Kaiser Permanente and Lloydspharmacy. For more information, please visit
www.proteusdigitalhealth.com.
About Otsuka Pharmaceutical Co., Ltd.
Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare
company with the corporate philosophy: 'Otsuka-people creating new products
for better health worldwide.' Otsuka researches, develops, manufactures and
markets innovative and original products, with a focus on pharmaceutical
products for the treatment of diseases and consumer products for the
maintenance of everyday health. Otsuka is committed to being a corporation
that creates global value, adhering to the high ethical standards required of
a company involved in human health and life, maintaining a dynamic corporate
culture, and working in harmony with local communities and the natural
environment.
Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka
Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group
has business operations in 24 countries and regions around the world, with
consolidated sales of ¥1,154.6 billion for fiscal year 2011. For more
information, visit www.otsuka.co.jp/en.
Contact:
Proteus Digital Health, Inc.
Marnell Mullarkey, +1-650-637-6114
mmullarkey@proteusdh.com
or
Elizabeth J. Hutter, MPH, +1-212-259-0490
ehutter@wcgworld.com
or
Otsuka
Otsuka America Pharmaceutical, Inc.
David Caruba, +1-609-524-6798
david.caruba@otsuka-us.com
or
Otsuka Pharmaceutical Co., Ltd.
Masamitsu Kitada, +81-3-6361-7379
kitadams@otsuka.jp
